Quanterix (NASDAQ:QTRX) Cut to “Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Quanterix (NASDAQ:QTRX) from a hold rating to a sell rating in a research note issued to investors on Sunday morning.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Quanterix in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $11.33.

Quanterix Stock Performance

NASDAQ QTRX opened at $6.64 on Friday. The company has a market capitalization of $310.15 million, a P/E ratio of -2.85 and a beta of 1.01. The stock has a 50 day moving average price of $6.29 and a 200-day moving average price of $5.81. Quanterix has a one year low of $4.05 and a one year high of $12.41.

Quanterix (NASDAQ:QTRX) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.13). Quanterix had a negative return on equity of 21.34% and a negative net margin of 73.47%.The business had revenue of $40.23 million during the quarter, compared to analysts’ expectations of $37.85 million. As a group, equities analysts predict that Quanterix will post -0.98 EPS for the current fiscal year.

Hedge Funds Weigh In On Quanterix

A number of large investors have recently bought and sold shares of QTRX. Charles Schwab Investment Management Inc. raised its position in shares of Quanterix by 9.8% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 292,805 shares of the company’s stock worth $1,906,000 after acquiring an additional 26,190 shares in the last quarter. Invesco Ltd. grew its stake in Quanterix by 61.0% in the first quarter. Invesco Ltd. now owns 54,194 shares of the company’s stock valued at $353,000 after purchasing an additional 20,540 shares during the last quarter. Nuveen LLC bought a new position in Quanterix in the first quarter worth about $2,704,000. American Century Companies Inc. grew its position in shares of Quanterix by 9.9% in the 1st quarter. American Century Companies Inc. now owns 79,130 shares of the company’s stock worth $515,000 after buying an additional 7,138 shares during the last quarter. Finally, Quantbot Technologies LP increased its position in shares of Quanterix by 245.9% during the first quarter. Quantbot Technologies LP now owns 11,272 shares of the company’s stock worth $73,000 after purchasing an additional 8,013 shares in the last quarter. Institutional investors own 86.48% of the company’s stock.

Quanterix Company Profile

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company’s core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.